Brec1

Brec1 is an engineered site-specific recombinase developed by PROVIREX Genome Editing Therapies GmbH for the treatment of HIV/AIDS. It is designed to recognize and excise integrated HIV-1 proviral DNA from the genome of infected host cells by targeting the long terminal repeats (LTRs) that flank the provirus. Unlike CRISPR-based methods that rely on cellular DNA repair mechanisms, Brec1 performs error-free genome editing. The therapy typically involves the ex vivo delivery of the Brec1 gene into a patient's hematopoietic stem cells using a lentiviral vector (LV-Brec1), followed by autologous transplantation. It has demonstrated the ability to excise more than 90% of known HIV-1 strains and subtypes.

Other names

Brec1 recombinaseBrec-1 recombinaseBrec 1 recombinaseBrec1-PROVIREXBrec-1-PROVIREXBrec 1-PROVIREX